Derek Finnegan Since the rescheduling of cannabis-based products for medicinal use in November 2018, the landscape for patients has shifted significantly. However, it is a mistake to credit the change in law alone for the proliferation of access. While the law opened the door, the digital healthcare infrastructure built by private clinics walked through it.
If you look at the growth of medical cannabis in the UK, you aren’t looking at a traditional pharmacy model. You are looking at the rapid adoption of remote healthcare normalization. For the first time, patients who were previously ignored by traditional pathways found a way to bridge the gap between their condition and a prescription.
The 2018 Legalization: A Legislative Paper Tiger
In November 2018, the UK government reclassified cannabis-based products for medicinal use (CBPMs). The legislation allowed specialist doctors—not GPs—to prescribe these products. However, the legislation was fundamentally cautious. It gave the power to prescribe, but it didn’t mandate the NHS to use it.
The NHS has maintained a policy of extreme caution, primarily due to a lack of large-scale clinical evidence compared to long-standing pharmaceuticals. As a result, the NHS route is largely restricted to a tiny subset of patients, primarily those with rare forms of epilepsy, chemotherapy-induced nausea, or spasticity related to multiple sclerosis. For everyone else, the “legal” route was practically non-existent on the public balance sheet.
The NHS didn’t build the clinics; private enterprise did. And they didn’t build them on high streets; they built them on servers.
The Role of Telemedicine Platforms UK
The growth of medical cannabis in the UK is inextricably linked to the emergence of specialized telemedicine platforms. These platforms provided the digital healthcare infrastructure necessary to bypass the geographic limitations of traditional medical consulting.
Before the digital-first era, a patient with a chronic pain condition would have to travel, potentially hours, to see a specialist who had the authority and the willingness to discuss cannabis-based medicine. That barrier—time, transport, and mobility—is a massive deterrent for patients who are already struggling with severe, debilitating conditions.
Telehealth, defined here as the delivery of healthcare services remotely via technology, and video consultations, which are the live, face-to-face digital meetings between a clinician and a patient, removed that friction. By digitizing the consultation process, clinics were able to centralize their specialist expertise, serving patients across the entire UK from a single hub.
What a Patient Needs Before the Appointment
As someone who spent years managing clinical workflows, I know that patients often underestimate the preparation required for these digital consultations. A specialist cannot legally or ethically prescribe cannabis-based products without a complete picture of your medical history. Before you log into that video consultation, ensure you have the following ready:
- A Summary Care Record (SCR): This is an electronic record of your medicines, allergies, and any bad reactions to medicines you have had. You can request this from your GP reception.
- Evidence of Prior Treatments: You must demonstrate that you have tried at least two licensed medications or treatments for your condition without success. A list of your medication history is essential.
- Diagnosis Confirmation: A formal letter or record from a consultant confirming your specific condition.
- Valid Photo ID: For identity verification, which is a regulatory requirement for all telemedicine platforms in the UK.
- A List of Current Symptoms: Be specific. When did the symptoms start? How do they impact your daily life? How do they rank on a pain scale?
Defining the Product: A Quick Guide
When you start these consultations, you will inevitably hear terms that sound like science fiction. It is important to understand what you are being prescribed.
Cannabinoids are active chemical compounds found in the cannabis plant, such as THC and CBD, that interact directly with the body’s internal endocannabinoid system to regulate functions like pain, mood, and sleep. Terpenes are the aromatic oils produced by the cannabis plant that give it its distinct scent and are believed to influence the therapeutic effects of the medicine through what is known as the “entourage effect.”
The Access Gap: NHS vs. Private
The disparity between the public and private sectors in this space is stark. The table below outlines why patients have migrated toward digital private clinics.
Remote Healthcare Normalization and its Risks
The normalization of remote healthcare has been a net positive for access, but it hasn’t come without challenges. The ease of access can sometimes lead to an expectation of “miracle cures.” I want to be clear: medical cannabis is a tool for symptom management, https://www.timesargus.com/uk-health-policy-the-rise-of-cannabis-strains-prescriptions/article_d927b1bb-06fc-44c2-ae32-c787f7b74463.html not a cure-all.
The clinic is responsible for your safety, but you are responsible for your information. If a clinic promises you life-changing results without a thorough assessment of your existing medical background, that is a red flag. A reputable provider will prioritize patient safety—checking for drug interactions and psychiatric history—over the speed of the transaction.
The shift to digital-first patient journeys has effectively democratized the ability to *speak* to a specialist. However, the quality of that relationship depends on the clinic’s digital infrastructure. You should look for providers who integrate their telemedicine platforms with electronic prescription services (EPS), which allows the prescription to be sent directly to a specialized pharmacy, streamlining the entire workflow.
The Verdict: Is Telehealth the Main Driver?
Is telehealth the main reason medical cannabis became more common in the UK? Yes, it is the primary logistical engine.
Without the remote healthcare infrastructure, medical cannabis in the UK would have remained a niche, hyper-localized experience. Telehealth platforms solved the geographic barrier that the 2018 legislation inadvertently created by limiting who could prescribe the medicine. By centralizing specialists and utilizing video consultations, private clinics created a scalable, national model for patients who had run out of traditional options.
However, we must distinguish between “common access” and “equitable access.” While telehealth made medical cannabis more common, the barrier remains financial. Because the NHS has remained largely absent from the prescription space, the cost falls on the patient. Telehealth made the process possible, but it did not make it cheap.
For the future of UK patient care, the goal should be the integration of these digital efficiencies back into the wider public health framework. Until that happens, private telehealth remains the only viable path for the majority of patients seeking this form of treatment.
Final Thoughts for the Patient
If you are considering this route, stop looking for “miracles.” Instead, look for a clinic that values your data, takes the time to review your full history, and uses a secure, CQC-compliant digital platform. Your health is not a transactional service; it is a clinical process that requires documentation, patience, and a clear understanding of the risks and benefits. Gather your records, find a clinic that respects the weight of your history, and proceed with your eyes open.
